Federal contract award

W911NF25PA012

THIS PHASE I EFFORT WILL EXPLORE THREE STABILIZATION STRATEGIES--DIRECTED MUTAGENESIS, POLYMER-BASED NANOPARTICLE ENCAPSULATION, AND COVALENT ENZYME FUNCTIONALIZATION--TO GENERATE ROBUST PTE-BASED THERAPEUTICS READY FOR PHASE II DEVELOPMENT.

Research the contractorView USAspending sourceSave to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

FieldReported value
AgencyDepartment of Defense
OfficeW6QK ACC-APG DURHAM
NAICS541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSCAJ11 — GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH
Parent award / vehicleNot reported
Set-asideSMALL BUSINESS SET ASIDE - TOTAL
Pricing typeFIRM FIXED PRICE
Obligations$209.5K
Current contract value$209.5K
Potential contract value / ceiling$209.5K
Start dateAug 18, 2025
Current end dateFeb 17, 2026
Potential end dateFeb 17, 2026
Latest award activityNov 20, 2025
Source loadedSep 19, 2026

Funding and modification history

Showing the latest 2 of 2 loaded transactions. Negative values are deobligations.

DateModificationObligation changeDescription
Nov 20, 2025P00001$0THIS PHASE I EFFORT WILL EXPLORE THREE STABILIZATION STRATEGIES--DIRECTED MUTAGENESIS, POLYMER-BASED NANOPARTICLE ENCAPSULATION, AND COVALENT ENZYME FUNCTIONALIZATION--TO GENERATE ROBUST PTE-BASED THERAPEUTICS READY FOR PHASE II DEVELOPMENT.
Jul 25, 20250$209.5KTHIS PHASE I EFFORT WILL EXPLORE THREE STABILIZATION STRATEGIES--DIRECTED MUTAGENESIS, POLYMER-BASED NANOPARTICLE ENCAPSULATION, AND COVALENT ENZYME FUNCTIONALIZATION--TO GENERATE ROBUST PTE-BASED THERAPEUTICS READY FOR PHASE II DEVELOPMENT.

Research next steps

  1. Check the stated set-aside against the solicitation and current certifications.
  2. Review the award scope and buyer evidence before making a bid/no-bid decision.